Anti-anaphylactic activities of a new benzopyranopyridine derivative Y-12,141 in rats and guinea pigs.

Publisher Website
Google Scholar
Abstract
The active anaphylactic bronchoconstriction of rats mediated by IgE-like antibody against DNP[2,4-dinitrophenyl sulfonic acid]-Ascaris was inhibited by i.v. and intratracheal treatment with Y-12,141 [9-chloro-5-oxo-7-(1H-tetrazol-5-yl)-5H-[1]benzopyrano[2,3-b]pyridine sodium salt pentahydrate] in a dose-dependent manner. In both routes, the inhibitory effect of Y-12,141 on this response was more potent than that of disodium cromoglycate (DSCG). The oral administration of Y-12,141 produced a similar inhibition of the response. The passive anaphylactic bronchoconstriction of guinea pigs mediated by IgG-like antibody against egg albumin was prevented dose-dependently by treatment with Y-12,141 given i.v., but not with DSCG. Y-12,141 may be effective for the treatment of allergic bronchial asthma.